ビノレルビン二酒石酸塩
|
|
|
- CAS番号.
- 125317-39-7
- 化学名:
- ビノレルビン二酒石酸塩
- 别名:
- ビノレルビン二酒石酸塩;二酒石酸ビノルエルビン;酒石酸ビノレルビン;ビノレルビン 二酒石酸塩 水和物;ビノレルビン酒石酸塩;ビノレルビン酒石酸塩 (JAN)
- 英語名:
- Vinorelbine tartrate
- 英語别名:
- NAVELBINE;VINORELBINE DITARTRATE;NVB;VINORELBINE BITARTRATE;c’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxy;Vinorelbin Tartrate;VINORELBINE TARTRATE USP STANDARD;3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate;(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylicacidmethylester;KW-2307
- CBNumber:
- CB8761554
- 化学式:
- C53H66N4O20
- 分子量:
- 1079.11
- MOL File:
- 125317-39-7.mol
|
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 主な危険性 |
Xi |
|
|
| Rフレーズ |
43 |
|
|
| Sフレーズ |
26-36 |
|
|
| RIDADR |
UN 1544PSN1 6.1 / PGII |
|
|
| WGK Germany |
3 |
|
|
| HSコード |
29339900 |
|
|
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H317 |
アレルギー性皮膚反応を起こすおそれ |
感作性、皮膚 |
1 |
警告 |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
|
| 注意書き |
| P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
|
ビノレルビン二酒石酸塩 価格
もっと(17)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01W0122-0164 |
ビノレルビン二酒石酸塩 98.0+% (HPLC)
Vinorelbine Ditartrate 98.0+% (HPLC) |
125317-39-7 |
10mg |
￥15000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCV315000 |
ビノレルビン二酒石酸塩
Vinorelbine Ditartrate |
125317-39-7 |
10mg |
￥43500 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01TRCV315000 |
ビノレルビン二酒石酸塩
Vinorelbine Ditartrate |
125317-39-7 |
50mg |
￥94900 |
2023-06-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
Y0001939 |
ビノレルビン 二酒石酸塩 European Pharmacopoeia (EP) Reference Standard
European Pharmacopoeia (EP) Reference Standard |
125317-39-7 |
Y0001939 |
￥19100 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
Y0001938 |
ビノレルビン 二酒石酸塩 European Pharmacopoeia (EP) Reference Standard
European Pharmacopoeia (EP) Reference Standard |
125317-39-7 |
Y0001938 |
￥22300 |
2024-03-01 |
購入 |
ビノレルビン二酒石酸塩 化学特性,用途語,生産方法
外観
白色〜わずかにうすい褐色, 結晶性粉末〜粉末
溶解性
水、メタノール、エタノール(99.5)に極めて溶けやすく、アセトンに溶けやすく、ヘキサンにほとんど溶けない。
用途
有糸分裂時に微小管の構成タ
ンパク質チューブリンに選択的に作用するこ
とにより、重合阻害作用を示します。
用途
がん研究用試薬
効能
抗悪性腫瘍薬, 微小管重合阻害薬
商品名
ナベルビン (協和発酵キリン)
使用上の注意
不活性ガス封入
化学的特性
Pale Yellow Powder
定義
ChEBI: The L-(+)-tartrate salt of vinorelbine.
一般的な説明
Vinorelbine ditartrate is available in 1- and 5-mL vials at aconcentration of 10 mg/mL for IV use. It is FDA approvedfor the treatment of NSCLC. The agent has also been usedin treating metastatic breast cancer, cervical cancer, uterinecancer, and lung cancer especially in older patients or thosewith physical difficulties. Vinorelbine is the most lipophilicof the vinca alkaloids because of modifications of thecatharanthine ring system and dehydration of the piperidinering. This allows the agent to be quickly taken up into cellsincluding lung tissue where concentrations are 300-foldhigher than plasma concentrations. This is 3 to 13 timeshigher than the lung concentrations seen with vincristine.The agent is highly protein bound (80%–91%) and metabolizedby CYP3A. The major metabolite seen is the 4-Odesacetylderivative, which is equally active with the parentbut only formed in small quantities. The agent is eliminatedprimarily (33%–88%) in the bile with some appearing inthe urine (16%–30%). The elimination half-life is 27 to43 hours. The toxicities seen for vinorelbine includemyelosuppression, which is dose limiting but ceases upondiscontinuation of drug. This is most commonly seen as aneutropenia, and patient’s neutrophil count should be monitoredprior to and during therapy to decrease the chanceof infection. Additional toxicities include nausea/vomiting,elevation of liver function tests, alopecia, generalized fatigue，and inappropriate secretion of antidiuretic hormone.Neurotoxicity is seen with vinorelbine but occurs to a lesserdegree compared with other vinca alkaloids because of itsdecreased affinity for axonal microtubules.
生物活性
Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC 50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC 50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.
ビノレルビン二酒石酸塩 上流と下流の製品情報
原材料
準備製品
ビノレルビン二酒石酸塩 生産企業
Global( 522)Suppliers
125317-39-7(ビノレルビン二酒石酸塩)キーワード:
- 125317-39-7
- VINORELBINEDITARTRATE SALT HYDRATE
- VINORELBINE TARTRATE, NAVELBINE
- VINORELBINE RELATED COMPOUND A4-O-DEACETYLVINORELBINE TARTRATE USP STANDARD
- VINORELBINE TARTRATE, USP
- VinorelbineTartrateUsp28
- butanedioate(1:2)
- NAVELBINE TARTRATE
- VINORELBINE DITARTARIC ACID
- VINORELBINE DITARTRATE SALT
- VINORELBINE TARTRATE
- VINORELBINE(RG)
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12b,19a)-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (salt)
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12R,19a)-, (2R,3R)-2,3-dih
- C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:2) (salt)
- Navelbine ditartrate
- Nor-5'-anhydrovinblastine ditartrate
- 5'-NORANHYDROVINOBLASTINE TARTRATE
- 3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE [R-(R*,R*)-2-3-DIHYDROXYBUTANEDIOATE (1:2) SALT]
- Pacilitaxel
- Vinorelbine ditartrate, Vinorelbine bitartrate, VRLB,KW – 2307 NVB
- KW-2307
- Vinorelbine Bitartarate
- Vinorelbine ditartrate salt hydrate,3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartr
- Vinorelbine Tartrate (200 mg)
- Methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(1R,12S,14R)-16-ethyl-12-(Methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4(9),5,7,15-pentaen-12-yl]-10-hydroxy-5-Methoxy-8-Methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0
- Vinorelbine ditartate
- lbine Ditartrate
- Vinoreline Tartrate
- 5μ-Noranhydrovinoblastine tartrate, KW-2307, Navelbine tartrate, NVB, 3μ,4μ-Didehydro-4μ-deoxy-Cμ-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt]
- Vinorelbine hydrate ditartrate salt
- ビノレルビン二酒石酸塩
- 二酒石酸ビノルエルビン
- 酒石酸ビノレルビン
- ビノレルビン 二酒石酸塩 水和物
- ビノレルビン酒石酸塩
- ビノレルビン酒石酸塩 (JAN)